S&P Futures
4,157.75 +11.00 (+0.27%) Dow Futures
32,821.00 +64.00 (+0.20%) Nasdaq Futures
13,289.00 +60.25 (+0.46%) Russell 2000 Futures
1,925.60 +3.80 (+0.20%) Crude Oil
88.59 -0.42 (-0.47%) Gold
1,789.20 -2.00 (-0.11%)
Reckitt Benckiser Group plc (3RB.F)
Chart Events
Performance Outlook
| Previous Close | 79.00 |
| Open | 79.10 |
| Bid | 79.90 x N/A |
| Ask | 80.20 x N/A |
| Day's Range | 79.10 - 80.00 |
| 52 Week Range | 64.30 - 82.10 |
| Volume | |
| Avg. Volume | 627 |
| Market Cap | 57.153B |
| Beta (5Y Monthly) | 0.10 |
| PE Ratio (TTM) | 15.87 |
| EPS (TTM) | 5.04 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.05 (2.60%) |
| Ex-Dividend Date | Aug 04, 2022 |
| 1y Target Est | N/A |
- Financial Times
Reckitt gains from rising medicine sales as Covid-19 beds in
Strepsils-maker and rival Haleon benefit from over-the-counter treatments boost from Omicron, colds and flu
- Financial Times
Haleon/Reckitt Benckiser: Covid offers cold cure makers a long-lasting boost
Colds and flu put on a lockdown disappearing act. It buoyed Haleon’s half-year results and those of rival Reckitt Benckiser on Wednesday. It is a similar story from Haleon, which reported that sales of its Theraflu medicine more than doubled.
- Benzinga
Reckitt Lifts Annual Forecast On Higher Prices, Baby Formula Shortage
Reckitt Benckiser Group PLC (OTC: RBGLY) said Q2 like-for-like revenue rose 11.9% on a constant currency basis, beating the 6.8% growth analysts had expected in a company-supplied poll. Reckitt hiked prices 9.7% in the quarter, while sales volumes were up 2.2%. Q2 sales increased 5.9% on constant currency to ÂŁ3.46 billion, including a 3.3% boost from sales of its Enfamil baby formula amid a shortage of supplies in the U.S. after Abbott Laboratories (NYSE: ABT) recalled dozens of brands in Februa
